Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma

Fozza, Claudio and Galleu, Antonio and Careddu, Maria Grazia and Giannico, Barbara Domenica and Bonfigli, Silvana and Contini, Salvatore and Longinotti, Maurizio Roberto (2010) Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma. Annals of Hematology, Vol. 89 (1), p. 113-114. eISSN 1432-0584. Article.

Full text not available from this repository.

DOI: 10.1007/s00277-009-0782-y

Abstract

Autoimmune manifestations including autoimmune hemolytic anemia (AIHA) are often described in association with splenic marginal zone lymphoma (SMZL) [1]. Moreover, AIHA has been recently reported as a potential risk factor of poor outcome for SMZL patients [2]. Among the different available therapeutic options, rituximab monotherapy has been recently shown to be extremely effective in SMZL [3]. On the other hand, this monoclonal antibody plays a key role in the treatment of steroid-refractory AIHA [4]. More specifically, although rituximab has been recently included among the possible strategies to treat AIHA secondary to chronic lymphocytic leukemia [5], very few cases describing its use in the course of SMZL-related AIHA have been described so far [6].

Item Type:	Article
ID Code:	4421
Status:	Published
Refereed:	Yes
Uncontrolled Keywords:	Bilirubin, CD19 antigen, CD20 antigen, CD22 antigen, CD5 antigen, complement component C3d, glycoprotein p 15095, haptoglobin, hemoglobin, immunoglobulin kappa chain, immunoglobulin M, lactate dehydrogenase, methylprednisolone, rituximab
Subjects:	Area 06 - Scienze mediche > MED/15 Malattie del sangue
Divisions:	001 Università di Sassari > 03 Istituti > Ematologia
Publisher:	Springer Berlin / Heidelberg
eISSN:	1432-0584
Copyright Holders:	© Springer-Verlag 2009
Deposited On:	31 Aug 2010 19:07

I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore

Repository Staff Only: item control page